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TO THE EDITOR 
Telomeres are tandem repeats of the non-coding DNA structures at the end of human 
chromosomes that protect the coding DNA and the integrity of the genome (Blackburn, 
1991). The ability to sustain telomere length confers unlimited proliferative capacity to 
cancer cells. In a majority of cancers, telomere length is maintained by the activity of the 
enzyme telomerase (Kim et al., 1994), whose catalytic subunit is encoded by the 
telomerase reverse transcriptase (TERT) gene. However, until recently, the underlying 
mechanisms for telomerase activation in cancer cells were largely unknown.  
 
Recurrent transcription activating mutations of the TERT promoter were first described 
in melanoma and subsequently in other tumor types (Horn et al., 2013; Vinagre et al., 
2013). These mutations upregulate TERT expression by recruiting the multimeric GA-
binding protein transcription factor that specifically binds to the mutant promoter (Bell et 
al., 2015). In addition to the mutations, DNA methylation of the TERT promoter is likely 
to play a role in TERT expression (Guilleret and Benhattar, 2004). Recently, it was 
shown that a region of the TERT promote upstream of the transcription start site is 
methylated in malignant telomerase-expressing pediatric brain tumors but not in 
telomerase-negative normal brain tissue (Castelo-Branco et al., 2013).  
 
We previously showed that an aggressive form of pediatric melanoma developing within 
giant congenital nevi (GCN) retains the wild-type TERT promoter (Lu et al., 2015). To 
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determine whether epigenetic modifications may play a role in telomerase expression in 
this melanoma subtype, we analyzed the DNA methylation profile of a CpG-rich region 
of the TERT promoter, shown previously to be differentially methylated between normal 
and malignant tissues (Castelo-Branco et al., 2013), in 13 melanomas (3 arising in 
GCN; 7 conventional; and 3 spitzoid) and 10 benign or borderline melanocytic tumors (1 
GCN; 3 GCN with nodular proliferation; and 6 borderline spitzoid melanocytic 
neoplasms) from 23 pediatric and adult patients. The human investigations were 
performed after approval by the local institutional review boards. Written, informed 
patient consent was waived because the research involved no more than minimal risk to 
the subjects. The status of the TERT promoter, BRAF and NRAS mutations, and kinase 
fusions was available for the spitzoid tumors and a subset of melanoma samples from 
our prior studies (Lee et al., 2015; Lu et al., 2015). 
 
Supplementary Table S1 and Figure 1 summarize the demographic and outcome data 
and the primary driver oncogene for the 23 study subjects. PCR–Sanger sequencing 
identified a hotspot TERT promoter mutation [4 C228T (chr5:1,295,228); 3 C250T (chr5: 
1,295,250), and 2 CC242/243TT (chr5: 1,295,242-3)] in 9 of 13 melanoma samples (6/7 
conventional; 3/3 spitzoid) but not in the 10 benign or borderline melanocytic neoplasms 
(Figure 1). The DNA methylation status of a region of the TERT promoter, from 482 bp 
to 667 bp upstream of the ATG start site [chr5:1295586−1295771 (GRCh37/hg19)] 
(Supplementary Figure S1 online), encompassing 26 CpG sites, was assayed by next-
generation bisulfite sequencing (Methods, Supplementary Material online). For each 
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CpG site, the methylation ratio (Beta-value) was measured in the range of 0 to 1 
(Supplementary Table S2 online). The methylation status was defined as follows: >0.7, 
methylated (Figure 1, red); 0.5–0.7, partially methylated (orange); 0.3 to <0.5, partially 
unmethylated (cyan); and <0.3, unmethylated (blue). Supplementary Table S3 shows 
the total number of methylated Cs and unmethylated Cs in the sequenced region for 
each sample. Remarkably, almost all 26 CpG sites in the sequenced region were highly 
methylated in the 3 melanomas arising in GCN (S1, S2, S21), and the one conventional 
melanoma bearing wild-type TERT promoter (S22), whereas the CpG sites remained 
predominantly unmethylated in the 9 mutant TERT promoter melanomas and the 10 
benign or borderline melanocytic neoplasms (Figure 1).  
 
Next, we evaluated the association of TERT promoter CpG methylation with telomerase 
expression by TERT mRNA in situ hybridization (ISH) and by gene expression analysis 
(Methods, Supplementary Material online). TERT mRNA ISH revealed distinct, 
intracellular punctate signals in melanomas arising in GCN (Figure 2c and 2f) but not in 
the proliferative nodules in GCN (Figures 2i and 2l). The TERT promoter methylation 
level was calculated as the log2 ratio of the total number of methylated Cs versus the 
total number of unmethylated Cs in the sequenced region [logit (B-value)]. The TERT 
expression level was measured by using RNA sequence data available for a subset of 
samples. An association analysis revealed a strong correlation between TERT promoter 
methylation and TERT expression level (P = 0.0422, adjusted r2 = 0.5145; 
Supplementary Figure S2 online). 
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Our data demonstrate that epigenetic modification through TERT promoter CpG 
methylation is an alternative pathway for TERT reactivation in melanoma. Although 
epigenetic remodeling by promoter methylation is generally considered a signature of 
gene silencing, TERT expression is paradoxically increased by promoter methylation 
(Guilleret and Benhattar, 2004).  Although the exact mechanism underlying CpG DNA 
methylation in TERT upregulation is not known, one possible mechanism is by inhibiting 
transcriptional repressors such as CTCF (Renaud et al., 2007), SIN3A , or MAZ (Xu et 
al., 2013) from binding to the target DNA-binding sites in the region (Figure S1). Also, 
even when the promoter is largely methylated, a small region of the core promoter 
upstream of the transcription start site remains unmethylated to allow for the continued 
transcriptional activity of TERT (Renaud et al., 2007; Zinn et al., 2007). 
 
Individuals with GCN are at increased risk for developing melanoma (Figures 2a-b and 
2d-e) that occurs most frequently in the first decade of life (Bittencourt et al., 2000). A 
much more frequent change in these nevi than melanoma is the development of clonal 
proliferations often in the form of nodules (Figures 2g-h and 2j-k), which may suggest or 
mimic melanoma on clinical or histological grounds (Yelamos et al., 2014). The 
differential pattern for TERT promoter methylation and telomerase expression between 
melanomas in GCN and proliferative nodules demonstrated in our study is consistent 
with the benign clinical course of proliferative nodules compared with the invariably 
aggressive behavior of melanoma arising in GCN. Further studies in a larger number of 
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patients are needed to determine the potential diagnostic value of TERT promoter 
methylation assays for ambiguous proliferative lesions within GCN.  
 
In our cohort, TERT promoter hypermethylation or promoter mutations occurred in all 
melanoma samples but in none of the melanocytic lesions of low/borderline malignant 
potential, suggesting that a panel incorporating TERT promoter methylation and 
mutation assays may help discriminate between benign/borderline and overtly 
malignant melanocytic neoplasms. Future studies need to assess the potential use of 
these assays for diagnostic or prognostic purposes in the clinic. 
 
In summary, we demonstrate that in subsets of malignant melanoma, TERT is 
upregulated epigenetically by a methylation-dependent mechanism. These findings 
have potential therapeutic implications. TERT promoter CpG hypermethylation is a 
reversible phenomenon. Treatment with DNA demethylating agents reduced TERT 
expression and telomerase activity in telomerase-positive cell lines (Guilleret and 
Benhattar, 2003; Renaud et al., 2007). Together, these findings provide a rationale for 
developing a therapeutic strategy in preclinical studies through epigenetic modifications 
at TERT promoter regulatory sites in melanomas with a promoter methylator phenotype. 
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Figure Legends 
 
Figure 1  
Association of the mutational status and the methylation profile of the TERT promoter 
with disease characteristics and outcome data for 23 patients with melanocytic tumors. 
The 26 CpG sites were aberrantly methylated in wild-type TERT promoter melanomas 
(the last 4 rows) but were predominantly unmethylated in low-grade or benign 
melanocytic tumors (atypical spitzoid neoplasms and GCN with proliferative nodules) 
and in mutant TERT promoter melanomas. Methylation panel color code: M, 
methylated; PM, partially methylated; PUM, partially unmethylated; UM, unmethylated; 
NA, not available. 
 
Figure 2 
Photomicrographs (H&E–stained) and TERT mRNA in situ hybridization (ISH) for 2 
melanomas in GCN (2 top panels) and 2 proliferative nodules in GCN (2 bottom 
panels). mRNA ISH shows numerous high-resolution red intracellular punctate signals 
in malignant melanocytes (c and f) and no signals above the background level in 
melanocytes of proliferative nodules (i and l). Scale bars= 1000 µm (a) and 50 µm (b). 
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